David Gray has been involved in clinical drug development in the pharmaceutical and biotechnology industries for over twenty-five years including leadership positions in clinical operations and biostatistics. He feels fortunate to have participated in the development and approval of life-changing therapies including an aerosol antibiotic for cystic fibrosis and a targeted antibody drug conjugate for Hodgkin and T-cell lymphomas.
Nancy has a background in molecular biology and has over 20 years of experience in medical education and healthcare communications. Much of her professional experience has focused in the area of oncology, and has included oversight of grant funded educational programming, advisory board planning and execution, scientific communications and publication planning, clinical support and clinical trial awareness initiatives, as well as educational content development and dissemination.
Denise has over 30 years of varying experience in and out of the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency and effectiveness within the organization, as well as the daily processes and functions.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for second-line treatment.
Laya Dogmetchi is a 1993 graduate of the University of California at Irvine and earned her Juris Doctorate from Vermont Law School in 1996. She then attended the University of Washington School of Law, where she earned an LL.M. in “Marine Law and Affairs” in 1997. Laya has been practicing law in Southern California since 1997, and presently is a of counsel at the Law Firm of Zfaty Burns in Newport Beach, California.
The following content is offered by the moderators and is adapted from text that appears in several different posts and discussion threads on this topic.
Amy brings more than two decades of experience in for-profit and nonprofit business management and ownership. In December 2017, she joined The Global Resource for Advancing Cancer Education as its Executive Director. She directs its growth in revenue, outreach, and programs.
In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.
Sara was diagnosed with stage IV RET+ lung cancer in 2010. Traditional chemo and radiation followed with great success. In the years since Sara has been on and off treatment several times. She is currently taking nivolumab and doing very well. Sara lives in Dayton, OH with her husband, JD, and two daughters Katie and Elena. Katie just headed off to college at Washington University in St. Louis while Elena is in the 10th grade.
Vamsidhar Velcheti, MD, is a staff Physician of Medicine at the Cleveland Clinic Lerner College of Medicine and staff physician in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute. His specialty areas include lung cancer, mesothelioma, and thymic tumors and the use of novel immunotherapies for the treatment of lung cancer. Dr.